Skip to main content
Top
Published in: Journal of Neurology 3/2012

01-03-2012 | Original Communication

The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease

Authors: James Shearer, Colin Green, Carl E. Counsell, John P. Zajicek

Published in: Journal of Neurology | Issue 3/2012

Login to get access

Abstract

The aim of the study was to estimate health state utility values in newly diagnosed idiopathic Parkinson’s disease (PD) for use in the assessment of health-related quality-of-life (HRQL), and in the estimation of quality-adjusted life-years (QALYs). Data from 162 patients enrolled in a community-based incidence study of PD were used to estimate health state utility values. Self-report data from the EQ-5D, a generic measure of HRQL, were used to derive preference-based health state utility values. The impact of motor and non motor symptoms, and other clinical and demographic factors, on the derived EQ-5D health state values was examined in univariate and multivariate analyses. The mean health state utility value for recently diagnosed PD patients was estimated at 0.65 ± 0.27. Significant reductions in health state values were attributable to pain (−0.18), motor functioning (−0.16), depression (−0.12), and insomnia (−0.11). Depression had its greatest impact (−0.19) in patients in the less severe stages of PD (i.e. Hoehn Yahr stages ≤2.5). This study shows, through the presentation of QALY values, that there is scope to achieve significant health gains in newly diagnosed idiopathic PD patients via improved management of pain, depression and insomnia, alongside the treatment of primary motor symptoms.
Literature
1.
go back to reference Wickremaratchi MM, Perera D, O’Loghlen C et al (2009) Prevalence and age of onset of Parkinson’s disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 80:805–807PubMedCrossRef Wickremaratchi MM, Perera D, O’Loghlen C et al (2009) Prevalence and age of onset of Parkinson’s disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 80:805–807PubMedCrossRef
2.
3.
go back to reference Dowding C, Shenton C, Salek S (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721PubMedCrossRef Dowding C, Shenton C, Salek S (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721PubMedCrossRef
4.
go back to reference Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53:S3–S12PubMedCrossRef Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53:S3–S12PubMedCrossRef
5.
go back to reference Soh S-E, Morris M, McGinley J (2011) Determinants of health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 17:1–9PubMedCrossRef Soh S-E, Morris M, McGinley J (2011) Determinants of health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 17:1–9PubMedCrossRef
6.
go back to reference Gallagher D, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500PubMedCrossRef Gallagher D, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500PubMedCrossRef
7.
go back to reference Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies. Canadian Agency for Drugs and Technologies in Health, Ottawa Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies. Canadian Agency for Drugs and Technologies in Health, Ottawa
8.
go back to reference National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, London National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, London
9.
go back to reference Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Barton: Australian Government Department of Health and Ageing; 2008 Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Barton: Australian Government Department of Health and Ageing; 2008
10.
go back to reference Dorsey E, Meltzer D (2010) The economics of comparative effectiveness research. Neurology 75:492–493CrossRef Dorsey E, Meltzer D (2010) The economics of comparative effectiveness research. Neurology 75:492–493CrossRef
11.
go back to reference Caslake R, Moore J, Gordon J et al (2008) Changes in diagnosis with follow-up in an incident cohort of patients with Parkinsonism. J Neurol Neurosurg Psychiatry 79:1202–1207PubMedCrossRef Caslake R, Moore J, Gordon J et al (2008) Changes in diagnosis with follow-up in an incident cohort of patients with Parkinsonism. J Neurol Neurosurg Psychiatry 79:1202–1207PubMedCrossRef
12.
go back to reference Taylor K, Counsell C, Harris C et al (2006) Pilot study of the incidence and prognosis of degenerative Parkisonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 21:976–982PubMedCrossRef Taylor K, Counsell C, Harris C et al (2006) Pilot study of the incidence and prognosis of degenerative Parkisonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 21:976–982PubMedCrossRef
13.
go back to reference Fahn S, Elton R (1987) UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D (eds) Recent developments in Parkinson’s disease. vol 2. Macmillan Healtcare Information, Florham Park, NJ, 153–163 Fahn S, Elton R (1987) UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D (eds) Recent developments in Parkinson’s disease. vol 2. Macmillan Healtcare Information, Florham Park, NJ, 153–163
14.
go back to reference Goetz C, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 19:1020–1028PubMedCrossRef Goetz C, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 19:1020–1028PubMedCrossRef
15.
go back to reference Folstein M, Folstein S, McHugh P (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein M, Folstein S, McHugh P (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
16.
go back to reference Mahieux F, Michelet D, Manifacier M-E et al (1995) Mini-mental Parkinson: First validation of a new bedside test constructed for Parkinson’s disease. Behav Neurol 8:15–22 Mahieux F, Michelet D, Manifacier M-E et al (1995) Mini-mental Parkinson: First validation of a new bedside test constructed for Parkinson’s disease. Behav Neurol 8:15–22
17.
go back to reference Weintraub D, Oehlberg K, Katz I et al (2006) Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 14:169–175PubMedCrossRef Weintraub D, Oehlberg K, Katz I et al (2006) Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 14:169–175PubMedCrossRef
18.
go back to reference Wade D, Collin C (1988) The Barthel ADL Index: A standard measure of physical disability? Int Disabil Stud. 10:64–67PubMedCrossRef Wade D, Collin C (1988) The Barthel ADL Index: A standard measure of physical disability? Int Disabil Stud. 10:64–67PubMedCrossRef
20.
go back to reference Schrag A, Selai C, Jahanshahi M et al (2000) The EQ-5D––a generic quality of life measure––is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:67–73PubMedCrossRef Schrag A, Selai C, Jahanshahi M et al (2000) The EQ-5D––a generic quality of life measure––is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:67–73PubMedCrossRef
22.
go back to reference Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef
23.
go back to reference Siderowf A, Ravina B, Glick H (2002) Preference-based quality-of-life in patients with Parkinson’s disease. Neurology 59:103–108PubMed Siderowf A, Ravina B, Glick H (2002) Preference-based quality-of-life in patients with Parkinson’s disease. Neurology 59:103–108PubMed
24.
go back to reference Reuther M, Spottke E, Klotsche J et al (2007) Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13:108–114PubMedCrossRef Reuther M, Spottke E, Klotsche J et al (2007) Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13:108–114PubMedCrossRef
25.
go back to reference Vossius C, Nilsen OB, Larsen JP (2009) Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study. Drugs Aging 26:973–980PubMedCrossRef Vossius C, Nilsen OB, Larsen JP (2009) Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study. Drugs Aging 26:973–980PubMedCrossRef
26.
go back to reference Rahman S, Griffin H, Quinn N et al (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23:1428–1434PubMedCrossRef Rahman S, Griffin H, Quinn N et al (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23:1428–1434PubMedCrossRef
27.
go back to reference Roh JH, Kim BJ, Jang JH et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson’s disease. Acta Neurol Scand 119:397–403PubMedCrossRef Roh JH, Kim BJ, Jang JH et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson’s disease. Acta Neurol Scand 119:397–403PubMedCrossRef
28.
go back to reference Lee M, Walker R, Hildreth T et al (2006) A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag 32:462–469CrossRef Lee M, Walker R, Hildreth T et al (2006) A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag 32:462–469CrossRef
29.
go back to reference Beiske AG, Loge JH, Ronningen A et al (2009) Pain in Parkinson’s disease: Prevalence and characteristics. Pain Jan 141:173–177 Beiske AG, Loge JH, Ronningen A et al (2009) Pain in Parkinson’s disease: Prevalence and characteristics. Pain Jan 141:173–177
30.
go back to reference Forsaa E, Larsen J, Wentzel-Larsen T et al (2008) Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord 23:1420–1427PubMedCrossRef Forsaa E, Larsen J, Wentzel-Larsen T et al (2008) Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord 23:1420–1427PubMedCrossRef
31.
go back to reference Qin Z, Zhang L, Sun F et al (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771PubMedCrossRef Qin Z, Zhang L, Sun F et al (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771PubMedCrossRef
32.
go back to reference Li H, Zhang M, Chen L et al (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord 25:2740–2746PubMedCrossRef Li H, Zhang M, Chen L et al (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord 25:2740–2746PubMedCrossRef
33.
go back to reference Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157PubMedCrossRef Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157PubMedCrossRef
34.
go back to reference Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef
Metadata
Title
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease
Authors
James Shearer
Colin Green
Carl E. Counsell
John P. Zajicek
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 3/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6202-y

Other articles of this Issue 3/2012

Journal of Neurology 3/2012 Go to the issue